Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

http://www.wikidata.org/entity/Q35086789

about

Cytotoxic and targeted therapy for hereditary cancers Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies Trial watch - inhibiting PARP enzymes for anticancer therapy Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer The Role of Hedgehog Signaling in Tumor Induced Bone Disease Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways Recent advances in drug repositioning for the discovery of new anticancer drugs Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Basal cell carcinoma-treatments for the commonest skin cancer.Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.Identification of Novel Smoothened Ligands Using Structure-Based Docking.Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome.Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.Emerging drugs and combination strategies for basal cell carcinoma.Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.Optimal management of skin cancer in immunosuppressed patients.Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.Sonic hedgehog signaling in Basal cell nevus syndrome.Novel targets for the treatment of ameloblastoma.Regulation of the oncoprotein Smoothened by small molecules.Pharmacologic treatment options for advanced epithelial skin cancer.Repurposing itraconazole as an anticancer agent.Non-melanoma skin cancer: new and future synthetic drug treatments.Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.

P2860

Q26739366-5BC47CB0-3C08-4ACB-923B-3A4CB9559D55 Q26744173-A1BEBFFD-5766-4706-94BE-C6D482DE9E8A Q26745673-6252A24B-C2B5-40F0-9872-DF5E49171509 Q26775917-80583FC0-2308-490C-9B7A-2B206B745E04 Q26783028-7903F57C-0509-44DC-81B4-81305BB55262 Q26783615-18098AC6-DCB3-49B8-9EA6-218EFFAD9132 Q27027214-1EC3FFA1-CA45-43A3-BEF7-60A7AADC3A58 Q28078947-44015FF4-62DA-4245-92DF-C20B94E42A9E Q28391377-50E09717-D262-4907-8E95-A6F32F8B24DD Q33709769-0C103A57-32DE-481E-A05A-B9F4C73BCDDB Q33845068-7478F9A7-A6B8-4E0A-8C93-E7EA55FED558 Q33893928-CCC09E80-987E-4ACD-9DB1-7A57C1B65195 Q34437996-A6003F93-3BC5-4B03-94E2-5658A5C0B88E Q34474583-E23D6ECB-7C7B-4D6F-97D7-2E0DCEC9B6D3 Q35198596-248D691C-5DAE-4E11-8D2F-43264DC4EC89 Q35252021-AF7611A5-CA83-4D65-9055-3F9F186FA185 Q35552174-20AE1676-59AA-4B14-952C-8258FD67C425 Q35748908-8F40D43F-587C-4FB3-B2F6-952BB8FC7D2E Q35756696-25C50D67-476A-4F95-AE74-E06EE38ABCAD Q35822379-AF76529F-57FB-437E-AF6B-C5DAC3BCF0FB Q35904534-C1BB6312-265F-4439-A4A0-436AE5A852CF Q35915762-000D646F-2DA7-48CA-A750-B52EFA97B53E Q36094653-A433E957-D3C1-4E60-8339-73550213839B Q36435334-2D4F2508-972C-49A2-95F8-FEBD11638EEA Q36546794-063F05FD-0613-42A2-8703-3BE43808056B Q36803750-9A093B0C-2B7E-4AE1-AD2A-6DE747F9F36C Q36917768-A9796B4A-0620-4766-B49C-E33E8ACB9154 Q37747533-92CED08A-47EC-4011-A636-7BB4C3D06060 Q38207707-A2A5C1A6-8651-4C71-B07F-3162B5AD52A4 Q38213666-61F95E66-7B1C-4701-A43C-708832D1BF9C Q38228585-8C74B794-E7C8-4AC8-BD8C-2DEFF09A7BD2 Q38230602-B35B87F5-B564-4BD8-AF2F-BC7F5204F685 Q38244794-FE959238-4592-4434-8666-8C8A3FA0CF78 Q38271523-F785BC41-41FC-4DAF-89BC-EB504C0ABE93 Q38382683-8C0A3995-AD8A-4C82-9FBD-EA550EDDC92B Q38509273-2D73AC36-2E94-4A1C-B877-4B3F4E5158A9 Q38633691-3FA0A63B-53C5-4020-911F-DD8932EAFC6F Q38729673-88740672-1447-4B2D-B703-12373FA04651 Q38748824-BB787A51-A19B-4D2A-8A13-E2AC573B7AED Q38795323-190FBD75-E09E-4C31-A504-90E743962073

P2860

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

http://www.wikidata.org/entity/Q35086789

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@ast

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@en

type

label

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@ast

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@en

prefLabel

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@ast

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@en

P1433

Q35086789-75434B6D-B01F-4674-B092-DC0F1E43FC6B

P1476

Q35086789-A9CDB535-15F8-4E9F-A29E-B30061FEB381

P2093

Q35086789-288B739A-7EA9-47E9-BC05-C0EB02785C4C

Q35086789-370C58B6-58C2-4556-9AEF-4E20E3A86736

Q35086789-3F59BEE7-CBAD-4784-BCB8-7DF29930B0D3

Q35086789-557DB61C-6F18-4716-B788-C4BA6919E7EE

Q35086789-57F7CE95-A6B8-46CE-93BB-0872DCB3DBB0

Q35086789-6C376AFE-E250-40F6-A8F0-EC4E924D1AE0

Q35086789-C77311BA-DCEB-4DA4-B127-B66A0EDEB3A0

Q35086789-CC54D417-AE75-4274-AF33-12152CD2C70C

Q35086789-E7A77C25-56EA-4145-8D06-8709FCC6AADB

Q35086789-F22E4DBE-62A8-41E8-8523-47A63E0C5281

P304

Q35086789-78B13EF1-3EB0-4FCA-A4F7-DFD2B3DB22F5

P31

Q35086789-04B48CB0-664A-4C11-8EC8-60F89186ECC8

P356

Q35086789-863CACC8-7DDD-4BE4-B6AB-5DAFB96F62B5

P407

Q35086789-EC0D46E8-0AF3-484F-94B3-70A5A18E55E6

P433

Q35086789-909DF60F-BF88-4822-BA29-675AE89C0E76

P478

Q35086789-ECB195A1-FDC6-4961-BA85-328C674E00BB

P577

Q35086789-45FCF2BE-6BC1-46AA-A6C9-3132FB1D458C

P698

Q35086789-0BAFB1CB-7F10-43CD-9BF2-E920F8EC3455

P921

Q35086789-DFF8D3D6-A964-40FB-AA26-2A1F0886255D

P356

JCO.2013.49.9525

P1433

Journal of Clinical Oncology

P1476

Open-label, exploratory phase ...... tment of basal cell carcinoma.

@en

P2093

Anita Gilliam

http://www.w3.org/2001/XMLSchema#string

Daniel J Kim

http://www.w3.org/2001/XMLSchema#string

James Kim

http://www.w3.org/2001/XMLSchema#string

Javier Montoya

http://www.w3.org/2001/XMLSchema#string

Jean Y Tang

http://www.w3.org/2001/XMLSchema#string

Kalyani Chandra

http://www.w3.org/2001/XMLSchema#string

Katrina Spaunhurst

http://www.w3.org/2001/XMLSchema#string

Monserrat Molgo

http://www.w3.org/2001/XMLSchema#string

Philip A Beachy

http://www.w3.org/2001/XMLSchema#string

Rita Khodosh

http://www.w3.org/2001/XMLSchema#string

P304

745-751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.49.9525

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24493717

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial